Bachem stock holds steady as Barclays keeps Hold rating and CHF80 target

Published on 09/09/2026 at 21:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bachem stock trades near Barclays’ CHF80.00 target on September 9, 2026 after modest revenue and profit growth in the second quarter of 2026. The latest figures show low single-digit increases year on year, keeping expectations balanced.

Fotorealistische Peptid-Produktionsanlage mit Alpenpanorama im Hintergrund — Bachem Holding AG (CH0012530207) betreibt moderne Peptid-Produktionsanlagen mit Bioreaktoren vor Schweizer Alpenpanorama, Illustration mit AI erstellt.

Bachem Holding AG (ISIN CH0012530207) stock is trading close to a key analyst reference level on September 9, 2026, with the shares around the CHF78 to CHF79 range on SIX Swiss Exchange and year to date up more than 30 percent against the MSCI World benchmark.

Barclays sticks to Hold with CHF80 target

According to The Globe and Mail on September 9, 2026, Barclays analyst Charles Pitman maintained a Hold rating on Bachem Holding AG with a price target of CHF80.00, while the broader analyst consensus also stands at Hold with an average target at the same level.

An article from IT Boltwise dated September 9, 2026 reports that Barclays confirmed its Hold stance and CHF80.00 target, matching a consensus picture in which Bachem is neither aggressively favored nor underweight in analyst models.

Q2 2026 results show modest growth

Based on the latest earnings release for the quarter ending June 30, 2026, Bachem reported quarterly revenue of CHF326.45 million, up from CHF312.99 million in the prior-year quarter, an increase of about four percent that points to steady top line growth in its peptide and active pharmaceutical ingredient business, as summarized by The Globe and Mail.

In the same quarter, net profit reached CHF50.27 million, only slightly above the CHF50.10 million reported a year earlier, which means bottom line growth of less than one percent and indicates that margin expansion lagged revenue growth, according to the earnings data cited by The Globe and Mail.

IT Boltwise highlights that these Q2 2026 results are perceived as solid rather than spectacular, with the revenue increase of around four percent and almost flat net profit underlining why Barclays and the consensus remain cautious and stay with Hold ratings instead of upgrading Bachem despite its operational progress.

Avexitide contract underpins medium-term story

The same IT Boltwise report notes that Bachem Americas has secured a long term manufacturing and supply contract for the Avexitide compound with Amylyx Pharmaceuticals, a deal that strengthens Bachem’s pipeline of peptide contracts and supports visibility on medium term volumes in its contract manufacturing activities, as described by IT Boltwise.

IT Boltwise explains that the Avexitide agreement and the recently reported stable quarterly figures together shape the current narrative for Bachem stock on September 9, 2026, combining a fresh contract win with incremental financial improvement but not yet delivering the kind of earnings acceleration that would normally justify a rating upgrade or a significantly higher price target.

Stock trades near analyst target on SIX

On September 9, 2026, Yahoo Finance shows Bachem Holding AG quoted at CHF78.40 on SIX Swiss Exchange with a prior close of CHF78.60 and an intraday move of minus CHF0.20, equivalent to a daily decline of about 0.25 percent at 10:11 a.m. Central European time, while the stock’s YTD return stands at 32.57 percent versus 11.29 percent for the MSCI World index, indicating that Bachem has outperformed the global equity benchmark so far in 2026.

The same price overview from Yahoo Finance lists a 52 week band from CHF50.00 at the low end to CHF83.80 at the high, meaning that the current level around CHF78.40 leaves the shares less than seven percent below their 52 week high and more than 56 percent above the low, positioning Bachem stock closer to the upper part of its one year trading range as of September 9, 2026.

For investors, this positioning near both the consensus target of CHF80.00 and the 52 week high suggests that a significant part of the medium term optimism about contract wins and operational execution is already priced in, and that further upside would likely require either stronger than expected growth or a shift in analyst sentiment away from the current Hold consensus.

Stock price level and investor takeaway

Per SIX Swiss Exchange data summarized on Yahoo Finance, Bachem stock at CHF78.40 on September 9, 2026 is trading just about two percent below the CHF80.00 price target maintained by Barclays and the average of other analysts, and within the upper segment of its CHF50.00 to CHF83.80 52 week range, underlining a valuation that mirrors the cautious but constructive view embedded in current research coverage.